These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial. Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293 [TBL] [Abstract][Full Text] [Related]
11. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Martinon-Torres F; Wysocki J; Szenborn L; Carmona-Martinez A; Poder A; Dagan R; Richmond P; Gilbert C; Trudel MC; Flores S; Lupinacci R; McFetridge R; Wiedmann RT; Chen Q; Gerrits H; Banniettis N; Musey L; Bickham K; Kaminski J; Vaccine; 2023 May; 41(21):3387-3398. PubMed ID: 37105892 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study. Matur RV; Thuluva S; Gunneri S; Yerroju V; Reddy Mogulla R; Thammireddy K; Paliwal P; Mahantshetty NS; Ravi MD; Prashanth S; Verma S; Narayan JP Vaccine; 2024 May; 42(13):3157-3165. PubMed ID: 38637211 [TBL] [Abstract][Full Text] [Related]
13. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861 [TBL] [Abstract][Full Text] [Related]
14. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV. Wilck M; Barnabas S; Chokephaibulkit K; Violari A; Kosalaraksa P; Yesypenko S; Chukhalova I; Dagan R; Richmond P; Mikviman E; Morgan L; Feemster K; Lupinacci R; Chiarappa J; Madhi SA; Bickham K; Musey L; AIDS; 2023 Jul; 37(8):1227-1237. PubMed ID: 36939067 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial. Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033). Suzuki H; Fujita H; Iwai K; Kuroki H; Taniyama K; Shizuya T; Kishino H; Igarashi R; Shirakawa M; Sawata M Vaccine; 2023 Jul; 41(34):4933-4940. PubMed ID: 37344262 [TBL] [Abstract][Full Text] [Related]
18. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE). Simon JK; Staerke NB; Hemming-Harlo M; Layle S; Dagan R; Shekar T; Pedley A; Jumes P; Tamms G; Sterling T; Musey L; Buchwald UK; Vaccine; 2022 Feb; 40(9):1342-1351. PubMed ID: 35039194 [TBL] [Abstract][Full Text] [Related]
19. A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Bili A; Dobson S; Quinones J; Phongsamart W; Oberdorfer P; Kosalaraksa P; Dagan R; Richmond P; Wilck M; Vallejos W; Nunn C; McFetridge R; Tamms G; Fu R; Lupinacci R; Musey L; Banniettis N; Bickham K; Vaccine; 2023 Jan; 41(3):657-665. PubMed ID: 36522265 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]